Tuesday, December 7, 2021

CCTG MA.32 – A Phase III Randomized Double-Blind Placebo-Controlled Adjuvant Trial of Metformin vs Placebo in Early Breast Cancer

**Time:** Tuesday, December 7, 2021; 10:00 AM CT  
**Type:** Oral  
**Session:** General Session 1, Hall 3; 8:00 – 10:45 AM CT  
**Abstract:** CCTG MA.32, a phase III randomized double-blind placebo-controlled adjuvant trial of metformin (MET) vs placebo (PLAC) in early breast cancer (BC): Results of the primary efficacy analysis (clinicaltrials.gov NCT01101438)  
**Abstract #:** GS1-08  
**Page #:** 2446  
**Link:** [https://www.abstractsonline.com/pp8/#I/10462/presentation/2161](https://www.abstractsonline.com/pp8/#I/10462/presentation/2161)

Wednesday, December 8, 2021

CCTG MAC.15/SWOG S1007 – A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy Plus or Minus Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx For Positive Node, Endocrine Responsive Breast Cancer.

**Time:** Wednesday, December 8, 2021; 10:15 AM CT  
**Type:** Oral  
**Session:** General Session 2, Hall 3; 8:30 – 11:15 AM CT  
**Abstract:** Distant-disease free interval in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and her2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < or = 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG s1007 (RxPONDER)  
**Abstract #:** GS2-07

---

1Online abstracts are available on the SABCS website beginning March 2022. They are also viewable by using this link [https://www.sabcs.org/](https://www.sabcs.org/) and clicking on “To view the 2021 SABCS abstracts, please click here ...”. Page numbers are provided for easier reference.
Thursday, December 9, 2021

CCTG MA.9/SWOG S8814 – Phase III Comparison of Adjuvant Chemoendocrine Therapy with CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients with Involved Axillary Lymph Nodes and Positive Receptors

Time: Thursday, December 9, 2021; 7:00 – 8:30 AM CT
Type: Poster
Session: Poster Discussion
Abstract: Evaluation of the predicted sensitivity to endocrine therapy (SET2,3 index) and the 21-gene Breast Recurrence ScoreR assay in node-positive postmenopausal breast cancer: Results from an analysis in the SWOG S8814 trial

CCTG MAC.28/NRG BR007 – A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage 1, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score ≤18 Breast Cancer (DEBRA)

Time: Thursday, December 9, 2021; 7:00 – 8:30 AM CT
Type: Poster
Session: Poster Session 3
Abstract: Evaluating de-escalation of breast radiation (DEBRA) following lumpectomy for breast conservative treatment of stage 1, hr+, HER2-, RS ≤18 breast cancer: NRG-BR007 a phase III trial

Friday, December 10, 2021

CCTG MA.38 – Randomized Phase II Study Comparing Two Different Schedules of Palbociclib plus Second Line Endocrine Therapy in Women with Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer

Time: Friday, December 10, 2021; 7:00 – 8:30 AM CT
Elevated plasma IL-8 predicts for reduced outcomes in CCTG MA.38, a phase 2 randomized trial of palbociclib in ER+/HER2- metastatic breast cancer patients


Link: https://www.abstractsonline.com/pp8/#l/10462/presentation/1619